- Home
- RDZN vs TCRX Comparison
RDZN vs TCRX Comparison
Compare RDZN & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDZN
- TCRX
- Stock Information
- Founded
- RDZN 2015
- TCRX 2018
- Country
- RDZN United States
- TCRX United States
- Employees
- RDZN N/A
- TCRX N/A
- Industry
- RDZN Blank Checks
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- RDZN Finance
- TCRX Health Care
- Exchange
- RDZN Nasdaq
- TCRX Nasdaq
- Market Cap
- RDZN 75.2M
- TCRX 64.1M
- IPO Year
- RDZN N/A
- TCRX 2021
- Fundamental
- Price
- RDZN $1.31
- TCRX $0.98
- Analyst Decision
- RDZN Strong Buy
- TCRX Strong Buy
- Analyst Count
- RDZN 1
- TCRX 7
- Target Price
- RDZN $4.00
- TCRX $8.50
- AVG Volume (30 Days)
- RDZN 549.9K
- TCRX 977.3K
- Earning Date
- RDZN 11-14-2025
- TCRX 11-12-2025
- Dividend Yield
- RDZN N/A
- TCRX N/A
- EPS Growth
- RDZN N/A
- TCRX N/A
- EPS
- RDZN N/A
- TCRX N/A
- Revenue
- RDZN $48,035,296.00
- TCRX $8,423,000.00
- Revenue This Year
- RDZN $38.45
- TCRX $255.18
- Revenue Next Year
- RDZN $66.38
- TCRX N/A
- P/E Ratio
- RDZN N/A
- TCRX N/A
- Revenue Growth
- RDZN 3.42
- TCRX N/A
- 52 Week Low
- RDZN $0.68
- TCRX $0.96
- 52 Week High
- RDZN $2.99
- TCRX $4.94
- Technical
- Relative Strength Index (RSI)
- RDZN 47.81
- TCRX 26.41
- Support Level
- RDZN $1.32
- TCRX $1.02
- Resistance Level
- RDZN $1.50
- TCRX $1.25
- Average True Range (ATR)
- RDZN 0.19
- TCRX 0.15
- MACD
- RDZN -0.04
- TCRX -0.05
- Stochastic Oscillator
- RDZN 11.76
- TCRX 0.73
About RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.